Blocking CCR5/CCR5 ligand interaction by using fusion protein mCCR5–Ig-neutralizing CCR5 ligands, reduced migration, and immunosuppressive potential of MDSCs in the TME and significantly improved survival of tumor-bearing mice (199). Here, CCR5 is linked to neoplasm.